步长制药2025年上半年净利润同比增长171.24%

Core Viewpoint - The company reported a significant increase in net profit and revenue for the first half of 2025, indicating strong financial performance and growth potential in the pharmaceutical industry [1] Financial Performance - The company achieved an operating revenue of 5.664 billion yuan, representing a year-on-year growth of 4.27% [1] - The net profit attributable to shareholders reached 628 million yuan, showing a remarkable year-on-year increase of 171.24% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 619 million yuan, reflecting a year-on-year growth of 180.04% [1]